

Acute Coronary Syndrome (ACS)

Version:	7.0
Ratified by:	(Original) Clinical Guidelines Committee
Date ratified:	Updated July 2013, minor update January 2016, no change required October 2019
Name of originator/author:	Dr Thomas Kaier, Dr David Brull
Name of responsible committee/individual:	As above
Date re-issued:	October 2019
Review date:	October 2020
Target audience:	All clinicians, specifically ED and Cardiology staff.

A Whittington Hospital Clinical Management Guideline

Acute Coronary Syndrome describes a range of clinical scenarios where the patient presents with prolonged anginal chest pain at rest or on mild exertion with or without either ECG changes or myocardial injury (troponin rise).

Acute ST elevation myocardial infarction (STEMI) is a subset of ACS and we have incorporated the latest guidance into this document.


Summary of changes

- 3-hour Troponin "MI rule-out" (European Society of Cardiology guidelines)
- Ticagrelor (in place of Clopidogrel) for high-risk Non-ST Elevation ACS and for ST Elevation ACS
- ACS with high-risk clinical features and recurrent chest pain to be referred urgently for angiography within 24 hours of presentation.
- Involve Cardiology early in the management of high risk patients

ACS pathway version 02/10/2019

Clinical Suspicion of ACS

History, examination, serial ECGs, blood tests (FBC, U+Es, Troponin T, glucose, lipids) & GRACE score.



**ACS High Risk Clinical Features Recurrent/ongoing cardiac discomfort AND >1 of:

- ≥1mm ST depression or transient ST elevation
- Deep T-wave inversion V1-4
- Dynamic T wave inversion >2mm in >2 contiguous leads
- Haemodynamic instability (hypotension, pulmonary oedema)
- VT/VF due to myocardial ischaemia
- Troponin T > 0.1μg/l

ACS pathway version 02/10/2019

*Considerations regarding Ticagrelor prescribing

Please discuss with Cardiology

- 1. Ticagrelor is contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)
- 2. Ticagrelor should be avoided due to reduction in efficacy with strong CYP3A4 enzyme inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital)
- 3. Ticagrelor may not be tolerated due to side effects/adverse reactions (eg. unexpected bradycardia, dyspnoea)
- 4. Consider once-daily alternative (Prasugrel or Clopidogrel) if there is concern over patient compliance with Ticagrelor twice-daily dosing

Alternative to Ticagrelor in ST Elevation and high risk NSTEAC: Prasugrel

Loading dose 60 mg then 10 mg od (5mg od in >75 years, weight<60kg)

Consider Prasugrel

- 1. If Ticagrelor contraindicated or concern re. compliance
- 2. Particularly consider in diabetics
- 3. For treatment of acute stent thrombosis on Clopidogrel
- 4. Previous CVA/TIA is a contraindication to Prasugrel

Treat all patients (unless contraindicated)

- Dual antiplatelet therapy, (e.g. Aspirin 75mg od and either Clopidogrel 75mg od, Ticagrelor 90mg bd or Prasugrel 10mg od)
- Beta-blocker, e.g. Bisoprolol 1.25mg od (if contraindicated consider Diltiazem SR or Verapamil SR)

GRACE score

The scoring system can be used to predict in-hospital 6-month mortality and assess risk of future adverse cardiovascular events.

Online calculator: http://www.outcomes-umassmed.org/grace/acs-risk/acs-risk-content.html (iPhone version available for download)

Cardiology Cover

Whittington Cardiology SpR through bleep 3038 or 3096 (9am - 5pm)

Out of hours: Cardiology SpR at The Heart Hospital, 020 3456 7898 (bleep via switch)

Consider Clopidogrel for patients with high bleeding risk

(Age > 75yrs, high clinical risk of upper GI bleed, weight <60kg)

Treatment of Hyperglycaemia (blood glucose ≥ 10mmol/L)

Set up insulin sliding scale - proforma found on trust intranet within clinical guidelines. Check glucose hourly, aiming for blood glucose 4-8mmol/L.

If the patient is not known diabetic check glucose after an overnight fast 12 hours after discontinuation of insulin infusion.

Check HbA1C in all patients with hyperglycaemia on admission.

Check K+ at admission and 24 hours.

Refer to the diabetes team.

Risk Factor Modification

Offer all patients information and advice about their diagnosis and arrangements for follow-up.

Prior to discharge:

- Request an echocardiogram to assess LV function (optimize Heart function as appropriate)
- Actively manage cardiovascular risk factors (offer Nicotine Replacement Therapy) and introduce drug therapy for secondary prevention (Aspirin, Clopidogrel/Ticagrelor, beta-blocker, ACE inhibitor, statin)
- Promote **lifestyle changes** (smoking cessation, diet and exercise advice)
- Refer for cardiac rehabilitation (please copy a discharge letter to cardiology secretaries, clinic 3A)

ACS pathway version 02/10/2019